The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders

Leukemia. 2017 Aug;31(8):1661-1670. doi: 10.1038/leu.2017.139. Epub 2017 May 9.


Malignant hematological diseases are mainly because of the occurrence of molecular abnormalities leading to the deregulation of signaling pathways essential for precise cell behavior. High-resolution genome analysis using microarray and large-scale sequencing have helped identify several important acquired gene mutations that are responsible for such signaling deregulations across different hematological malignancies. In particular, the genetic landscape of classical myeloproliferative neoplasms (MPNs) has been in large part completed with the identification of driver mutations (targeting the cytokine receptor/Janus-activated kinase 2 (JAK2) pathway) that determine MPN phenotype, as well as additional mutations mainly affecting the regulation of gene expression (epigenetics or splicing regulators) and signaling. At present, most efforts concentrate in understanding how all these genetic alterations intertwine together to influence disease evolution and/or dictate clinical phenotype in order to use them to personalize diagnostic and clinical care. However, it is now evident that factors other than somatic mutations also play an important role in MPN disease initiation and progression, among which germline predisposition (single-nucleotide polymorphisms and haplotypes) may strongly influence the occurrence of MPNs. In this context, the LNK inhibitory adaptor protein encoded by the LNK/SH2B adaptor protein 3 (SH2B3) gene is the target of several genetic variations, acquired or inherited in MPNs, lymphoid leukemia and nonmalignant hematological diseases, underlying its importance in these pathological processes. As LNK adaptor is a key regulator of normal hematopoiesis, understanding the consequences of LNK variants on its protein functions and on driver or other mutations could be helpful to correlate genotype and phenotype of patients and to develop therapeutic strategies to target this molecule. In this review we summarize the current knowledge of LNK function in normal hematopoiesis, the different SH2B3 mutations reported to date and discuss how these genetic variations may influence the development of hematological malignancies.

Publication types

  • Review

MeSH terms

  • Animals
  • Hematologic Diseases / genetics*
  • Hematologic Neoplasms / genetics
  • Humans
  • Intracellular Signaling Peptides and Proteins
  • Janus Kinase 2 / genetics
  • Mutation*
  • Myeloproliferative Disorders / genetics*
  • Polycythemia / genetics
  • Proteins / chemistry
  • Proteins / genetics*
  • Proteins / physiology


  • Intracellular Signaling Peptides and Proteins
  • LNK protein, human
  • Proteins
  • Janus Kinase 2